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Abstract
An increased incidence of Mycoplasma pneumoniae infections was
reported in 2011 in two cities in France, Bordeaux and Caen.
Two complementary molecular typing methods, PCR-RFLP on
adhesin P1 and multilocus variable number tandem repeat analysis
(MLVA), were used to determine whether this phenomenon was
clonal. In 2011, the percentage of M. pneumoniae-positive patients
doubled in both cities compared with 2010. Macrolide resistance
remained stable at 8.3% of patients. Eighteen MLVA types were
identiﬁed among 94 M. pneumoniae-positive specimens, demon-
strating that the phenomenon was multiclonal. Types P, J, U, X
and E were the most frequent and 81.6% of the strains were
adhesin P1 type 1.
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Mycoplasma pneumoniae causes community-acquired respira-
tory tract infections, particularly in school-aged children and
young adults. Epidemics occur periodically, at 3- to 7-year
intervals [1], and can last several months. An epidemic of
M. pneumoniae infection started in 2010 in Denmark [2]. Since
this date, a substantial increase in the incidence of M. pneu-
moniae infections has been reported in several European
countries [3–5], Israel [6] and Japan [7], making its spread a
worldwide phenomenon.
One major question is whether these surges in M. pneu-
moniae infections can be attributed to the spread of unique or
distinct clones. Unfortunately, most epidemiological reports
have not included genotyping data. Clonal spread has been
documented recently in which the clonal spread of a single
M. pneumoniae MLVA type J strain in children attending the
same primary school and in their household contacts was
reported [8]. On the other hand, the increased incidence of
infections in Jerusalem in 2010 was found to be polyclonal [9],
FIG. 1. Percentage and number of M. pneumoniae-positive patients detected in Bordeaux and Caen and the distribution of MLVA types detected in
M. pneumoniae-positive respiratory tract specimens. (a) Percentage of M. pneumoniae-positive patients in Bordeaux between 2000 and 2011 (among
a total of 29 805 specimens collected from 24 511 patients) and in Caen between 2010 and 2011 (among a total of 7609 specimens collected from
6431 patients). For each point, 95% CI and the total number of patients tested are presented in parenthesis. Comparison of percentage of
M. pneumoniae-positive patients was performed using the v2 test. (b) Distribution of M. pneumoniae-positive patients by month in Bordeaux and
Caen between January 2010 and January 2012. (c) Age distribution of M. pneumoniae-positive patients in Bordeaux and Caen in 2011. (d) Minimum
spanning tree for M. pneumoniae MLVA types detected in 2011 from M. pneumoniae-positive respiratory tract specimens according to the city. Each
circle represents a particular MLVA type. The number in parentheses indicates the number of patients infected with this M. pneumoniae MLVA type.
The distance between genotypes is expressed as the number of allelic changes. The colour of the circles indicates the city, dark grey for Bordeaux
and white for Caen. The numbering system of MLVA types A to X was described by Degrange et al. [14]; MLVA type 29, 2-4-6-7-2; MLVA type 35, 2-
3-6-7-2; MLVA type 36, 6-4-6-7-2; MLVA type 38, 4-4-5-6-2; MLVA type 41, 2-3-5-7-2. (e) Minimum spanning tree for M. pneumoniae MLVA types
detected from M. pneumoniae-positive respiratory tract specimens in 2011 according to the P1 adhesin type.. The colour of the circles indicates the
P1 adhesin type: dark grey for type 1, white for type 2, light grey for cases in which the type was not determined (see d for the minimum spanning
tree legend). For a and b, the criteria for M. pneumoniae infections were a positive result on M. pneumoniae-speciﬁc PCR, a positive culture,
complement ﬁxation test titres  1:64 and/or the presence of M. pneumoniae-speciﬁc IgM.
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as were cases in England and Wales that occurred during the
winters of 2010–2011 and 2011–2012, but fewer than 20
samples were analysed for each period in this study [3].
In this study, we report an increased incidence of
M. pneumoniae infections in 2011 in two cities in France:
Bordeaux, in the southwest of the country, and Caen, in the
northwest. We aimed to determine whether this phenome-
non was clonal or multiclonal using two complementary
M. pneumoniae molecular typing methods, PCR-RFLP of the
adhesin P1 gene and multilocus variable number tandem
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repeat analysis (MLVA). The incidence of macrolide resistance
was also determined.
Results from all specimens submitted for M. pneumoniae
diagnosis at the Department of Bacteriology of the University
Hospital of Bordeaux between 1 January 2000 and 31 January
2012 and at the Department of Virology of the University
Hospital of Caen during 2010 and 2011 were collected
retrospectively. Both departments received samples from
adult and paediatric wards. In Bordeaux, the diagnosis of
M. pneumoniae infection was based on real-time PCR ampli-
ﬁcation [10], culture in modiﬁed Hayﬂick medium [11] and
serology, including complement ﬁxation test and detection of
M. pneumoniae IgM using M. pneumoniae IgM-ELISA (Medac
Hamburg, Germany). In Caen, diagnosis was made using a
commercial ELISA to detect speciﬁc IgG and IgM (Immuno-
Well, BMD, Croissy Beaubourg, France) and commercial
multiplex PCR tests (RespiFinder® SMART 22, PathoFinder).
A total of 29 805 specimens from 24 511 patients were
submitted for M. pneumoniae diagnosis at the Bordeaux
hospital between 2000 and 2012, and 785 patients were
diagnosed with a M. pneumoniae infection (3.20%; 95% CI,
2.99–3.43) according to a positive PCR, a positive culture, a
complement ﬁxation test titre  1/64 and/or the presence of
M. pneumoniae-speciﬁc IgM. The percentage of M. pneumoniae-
positive patients ranged between 1.27 and 3.42% before 2010
(Fig. 1a); it was 2.33% in 2010 (2478 specimens tested from
2019 patients, 2119 by serology and 359 by both PCR and
culture) and it signiﬁcantly increased in 2011 (p 1.3 1011, v2
test) to reach a rate of 6.80% (2282 specimens tested from
1927 patients, 1848 by serology and 434 by both PCR and
culture). A signiﬁcant increased incidence of M. pneumoniae
infections was also observed in Caen (Fig. 1a), with the
percentage of infected patients doubling from 1.1% in 2010
(3797 specimens tested from 3218 patients, 485 by serology
and 3312 by PCR) to 2.3% in 2011 (3812 specimens tested
from 3213 patients, 399 by serology and 3413 by PCR) (p
0.0002, v2 test). The distribution of the number of cases of
M. pneumoniae infections by month revealed that the epidemic
in Bordeaux started in December 2010 (Fig. 1b). In Caen, the
epidemic started later, in autumn 2011, despite a peak in
August 2011 (Fig. 1b).
In 2011, in Bordeaux, the median age of M. pneumoniae-
positive patients was 8.5 years (interquartile range (IQR) 4.1–
36.8 years), ranging from 1 week old to 93 years old. In Caen,
the median age was 8.3 years (IQR 4.6–24.2 years), and
patients ranged from 2 months to 82 years old. The majority
of patients, 59.6% in Bordeaux and 67.1% in Caen, were aged
14 years or under, while 21.4% of patients in Bordeaux and
13.7% of patients in Caen were 15–44 years old (Fig. 1c). In
both cities, the age proﬁles of M. pneumoniae-positive patients
were similar to those in 2010 prior to the surge of M. pneu-
moniae infections. This age distribution was also similar to the
one reported in Scotland between 2008 and 2011, where a
majority of patients (53%) were aged 14 and under [12].
All respiratory tract specimens from patients detected
positive for M. pneumoniae by PCR in 2011 (44 specimens
from 39 patients in Bordeaux and 50 specimens from 50
patients in Caen) were typed using a PCR-RFLP method
targeting the P1 adhesin gene [13] and using the M. pneumo-
niae MLVA typing method [9, 14]. Macrolide resistance-
associated mutations in the 23S rRNA gene were searched
using a real-time PCR and melting curve analysis method [15].
Macrolide resistance-associated mutations were found in
8.8% and in 7.9% of patients out of 34 and 38 patients for whom
ampliﬁcation was obtained in Bordeaux and Caen, respectively
(Table 1). Thus the overall resistance rate was 8.3% of patients
(95% CI, 3.9–17.0). This rate of macrolide resistance remained
stable in Bordeaux compared with 2005–2007 [15]. Four
A2058G substitutions, one A2059G substitution and one
A2062G substitution (E. coli numbering) were identiﬁed. The
A2062Gmutation was previously reported in in vitro selection of
resistant mutants [16] but to our knowledge, this is the ﬁrst
instance in which this mutation has been identiﬁed in a
M. pneumoniae-positive clinical specimen. In Bordeaux and
Caen, 13 and 14 distinct MLVA types were identiﬁed, respec-
tively (Table 1, Fig. 1d). The MLVA types in Bordeaux were
similar to those in Caen with only a few exceptions (Fig. 1d). In
both cities, MLVA types P, U, J, E and X predominated, MLVA
types P, U and J being the three most frequent. In Bordeaux, the
proportion of type 1 strainswas 81.2% (26/32) in 2011 (Table 1).
Type 1 strains also predominated in Caen, at a proportion of
82.1% (32/39) (Table 1). Thus, the overall proportion of type 1
strains in both cities was 81.6% (95% CI, 71.1–89.0) (Fig. 1e).
Interestingly, a shift toward type 1 strains has been noted in
Bordeaux since 2009–2010. We have previously reported that
both PCR-RFLP types were present in the same proportion in
Bordeaux from 2000 to 2006 [17]. It was the same in 2007 and
2008, with 38.1% (8/21) and 50% (5/10) of type 1 strain,
respectively, then type 1 strains becamemore prevalent in 2009
and 2010, with 66.6% of type 1 strain (4/6 and 2/3, respectively),
to ﬁnally reach the rate of 81.2% of M. pneumoniae-positive
specimens in 2011. The alternation of the two types over time
has been described previously [1].
Our data demonstrate that the surge of M. pneumoniae
infections in 2011 in France was a multiclonal phenomenon, as
was the case in Israel, England and Wales [3, 9, 18], but that
the great majority of cases involved M. pneumoniae type 1
strains. The predominance of type 1 strains is consistent with
results from China, where 93% of strains from clinical isolates
collected in 2008 and 2009 were reported to be M. pneumo-
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TABLE 1. Characteristics of 94 M. pneumoniae-positive respiratory tract specimens collected at the Bordeaux and Caen
University Hospitals, France, in 2011
Citya
Specimen
designation Sourceb
Patient’s age
(years unless
speciﬁed)
Date of
collection
MLVA
typec
PCR-RFLP
type
Macrolide
resistance
genotyped
C C12-51 Nose 7 Feb.-11 U 1 wt
C C12-53 Nose 4 months Mar.-11 Nde nd no amp
C C12-54 NPA 6 months Apr.-11 E 1 no amp
C C12-55 Throat 12 May-11 U 1 wt
C C12-1 Nose 2 May-11 P 1 wt
C C12-2 Trach. asp. 21 Jun.-11 P 1 wt
C C12-3 Nose 6 Jun.-11 P 1 wt
C C12-4 Nose 10 Jul.-11 X 1 wt
C C12-5 Nose 30 Jul.-11 nd nd wt
C C12-6 NPA 2 Jul.-11 P 1 wt
C C12-7 Nose 67 Aug.-11 U 1 wt
C C12-8 Nose 43 Aug.-11 A 1 no amp
C C12-9 Nose 78 Aug.-11 35 1 wt
C C12-10 Nose 1 Aug.-11 35 1 wt
C C12-11 Nose 59 Aug.-11 nd nd no amp
C C12-12 NPA 9 months Aug.-11 X 1 wt
C C12-13 Nose 2 months Aug.-11 nd nd no amp
C C12-14 Nose 14 Aug.-11 P 1 wt
C C12-15 Nose 2 Aug.-11 nd nd no amp
C C12-16 Throat 18 Sep.-11 A 1 wt
C C12-17 ANP 10 Sep.-11 P 1 wt
C C12-18 Nose 3 Oct.-11 36 nd A2058G
C C12-19 Nose 4 Oct.-11 A 1 wt
C C12-20 Nose 4 Oct.-11 38 nd no amp
C C12-21 Nose 6 Oct.-11 V 2 wt
C C12-22 Throat 10 months Oct.-11 X 1 A2058G
C C12-23 Nose 1 Oct.-11 X 1 wt
C C12-24 Nose 3 Oct.-11 J 1 wt
C C12-25 Nose 9 Nov.-11 J 1 wt
C C12-26 Nose 4 Nov.-11 J 1 no amp
C C12-27 Nose 8 Nov.-11 G 2 wt
C C12-28 Nose 58 Nov.-11 nd nd no amp
C C12-29 Nose 3 Nov.-11 U 1 no amp
C C12-30 Nose 6 Nov.-11 U 1 wt
C C12-31 Nose 7 Nov.-11 P nd wt
C C12-32 Nose 25 Nov.-11 U 1 wt
C C12-33 NPA 7 Nov.-11 U 1 wt
C C12-34 Nose 12 Nov.-11 nd nd wt
C C12-35 Nose 4 Dec.-11 nd nd wt
C C12-36 Nose 8 months Dec.-11 P 1 wt
C C12-37 NPA 5 Dec.-11 U 1 no amp
C C12-38 Nose 29 Dec.-11 E 1 wt
C C12-39 Nose 5 Dec.-11 V 1 wt
C C12-40 NPA 1 Dec.-11 J 1 wt
C C12-41 Nose 73 Dec.-11 M 2 wt
C C12-42 NPA 16 Dec.-11 U 1 wt
C C12-43 BAL 62 Dec.-11 T 2 wt
C C12-44 Nose 60 Dec.-11 nd 2 A2058G
C C12-45 Nose 9 months Dec.-11 B 2 wt
C C12-46 Nose 82 Dec.-11 M 2 wt
B Mpn-4840 Throat 17 Jan.-11 nd nd no amp
B Mpn-4872 Throat 40 Jan.-11 J 1 wt
B Mpn-4838f Throat 5 Jan.-11 J 1 wt
B Mpn-4864f Throat 5 Jan.-11 J 1 wt
B Mpn-4837 Throat 9 Jan.-11 J 1 wt
B Mpn-4873 Throat 8 Jan.-11 J 1 wt
B Mpn-4883 Throat 4 Jan.-11 nd nd no amp
B Mpn-4885 Throat 1 Jan.-11 nd nd no amp
B Mpn-4845f Throat 4 Jan.-11 J 1 wt
B Mpn-4861f Throat 4 Jan.-11 J 1 wt
B Mpn-4889 Throat 38 Feb.-11 nd nd no amp
B Mpn-4940 Throat 54 Mar.-11 R 2 wt
B Mpn-4941 BAL 8 Mar.-11 U 1 wt
B Mpn-4945 NPA 4 Mar.-11 J 1 wt
B Mpn-4999 NPA 36 Apr.-11 X 1 wt
B Mpn-4977 Throat 39 Apr.-11 X 1 wt
B Mpn-4994 Trach. asp. 4 Apr.-11 J 1 wt
B Mpn-Lim1f NPA 10 May-11 I 1 wt
B Mpn-5063f Sputum 10 Jun.-11 I 1 A2059G
B Mpn-5079 Throat 2 Aug.-11 nd nd no amp
B Mpn-5087 Throat 7 Aug.-11 35 1 wt
B Mpn-5096 BAL 2 Aug.-11 41 2 A2062G
B Mpn-5104 Bronch. asp. 5 Aug.-11 nd nd wt
B Mpn-5094 NPA 3 Aug.-11 J 1 wt
B Mpn-5213 NPA 34 Sep.-11 P 1 wt
B Mpn-5160 BAL 5 Oct.-11 29 1 wt
B Mpn-5156 NPA 1 Oct.-11 29 1 wt
B Mpn-5149 NPA 3 Oct.-11 P 1 A2058G
B Mpn-5163 Throat 5 Oct.-11 E 1 wt
B Mpn-5144 Throat 1 Oct.-11 G 2 wt
B Mpn-5209 NPA 1 week Nov.-11 nd nd wt
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niae type 1 [19], and results from an Italian outbreak in 2010,
where 82% of the strains belonged to type 1 [20].
In conclusion, we conﬁrm that the recent increased
incidence of M. pneumoniae infection in France was not a
clonal spread but rather a multiclonal phenomenon. This is
certainly the result of the simultaneous spread of several
clones in the community, each of which was able to spread
clonally in a closed or semi-closed community, such as a family
or school. However, despite several distinct MLVA types, most
of these clones were characterized as adhesin P1 type 1.
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